Emergings In Brief, September 2013
This article was originally published in Start Up
Executive Summary
Brief profiles of these recently formed companies: ColoWrap, Enteris BioPharma, HealthTell, and Novelogics Biotechnology.
ColoWrap LLC
413 West Cornwallis Road
Durham, NC 27707
Phone: (919) 451-1803
Email: [email protected]
Web Site: www.colowrap.com
Management: James P. Hathorn, Co-founder, President & CEO; John Hathorn, Co-founder
Company Launched: March 2012
Financing To Date: $220,000
Investors: Angel investors
Partners/Alliances: NA
Industry Segment: Gastrointestinal Devices
Business: ColoWrap aims to make colonoscopies faster and more comfortable. Its disposable binder is placed around the abdomen of patients and exerts counter pressure against the sigmoid colon to prevent looping. The device also reduces the amount of pressure that physicians need to apply during the procedure.
Enteris BioPharma Inc.
83 Fulton StreetBoonton, NJ 07005
Phone: (973) 453-3518
Email: [email protected]
Web Site: www.enterisbiopharma.com
Management: Brian Zietsman, President & CFO; Nozer Mehta, PhD, CSO; Tim Saxon, VP Business Development; Paul Shields, PhD, VP Operations
Company Launched: August 2013
Financing To Date: Undisclosed
Investors: Victory Park Capital
Partners/Alliances: NA
Industry Segment: Drug Delivery
Business: A group of former Unigene execs have acquired the company’s Peptelligence platform and launched Enteris to develop oral formulations of peptide and small molecule drugs for pharma partners. The founders have also acquired what they describe as a “proven” nasal delivery technology as well as a recombinant manufacturing process.
HealthTell Inc.
145 South 79th Street
Chandler, AZ 85226
Phone: (480) 659-3510
Email: [email protected]
Web Site: www.healthtell.com
Management: Stephen Albert Johnston, PhD, CSO; Neal Woodbury, PhD, COO; Bill W. Colston, PhD, CEO; Kathryn F. Sykes, PhD, VP Research; David Smith, PhD, VP Operations; Ted Tarasow, PhD, VP Product Development
Company Launched: October 2012
Financing To Date: $4 million
Investors: Undisclosed
Partners/Alliances: Arizona State University
Industry Segment: In vitro Diagnostics
Business: Instead of directly measuring pathogens or other disease markers, HealthTell’s test for early detection of infections and various cancers assesses the body’s unique response, or so-called immunosignature, to a given disease.
Novelogics Biotechnology Inc.
110-5769 201A Street
Langley, British Columbia
Canada V3A 8H9
Phone: (778) 837-2561
Email: [email protected]
Web Site: www.novelogics.com
Management: I. Wayne Cheney, PhD, Co-founder, President & CSO; Elaine Allison, Co-founder & Head of Business Development
Company Launched: August 2013
Financing To Date: Undisclosed
Investors: Undisclosed
Partners/Alliances: NA
Industry Segment: Oncology Drug Discovery
Business: Novelogics intends to discover and develop monoclonal antibodies, delivered via a proprietary device, that target immunosuppression in cancer. Founder Wayne Cheney was senior manager of preclinical research at viDA Therapeutics.